<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19283915</article-id><article-id pub-id-type="pmc">2650615</article-id><article-id pub-id-type="publisher-id">copd-3-683</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Health-related quality of life in outpatients with COPD in daily practice: the <italic>VICE</italic> Spanish study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mart&#x000ed;n</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="af1-copd-3-683">1</xref><xref ref-type="corresp" rid="c1-copd-3-683"/></contrib><contrib contrib-type="author"><name><surname>Moro</surname><given-names>Jos&#x000e9; M Rodr&#x000ed;guez-Gonz&#x000e1;lez</given-names></name><xref ref-type="aff" rid="af2-copd-3-683">2</xref></contrib><contrib contrib-type="author"><name><surname>Izquierdo</surname><given-names>Jos&#x000e9; L</given-names></name><xref ref-type="aff" rid="af3-copd-3-683">3</xref></contrib><contrib contrib-type="author"><name><surname>Gobartt</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="af4-copd-3-683">4</xref></contrib><contrib contrib-type="author"><name><surname>de Lucas</surname><given-names>Pilar</given-names></name><xref ref-type="aff" rid="af2-copd-3-683">2</xref></contrib><on-behalf-of>The VICE Study Group</on-behalf-of></contrib-group><aff id="af1-copd-3-683"><label>1</label> Medical Department, Pfizer, Madrid, Spain</aff><aff id="af2-copd-3-683"><label>2</label> Service of Pneumology, HGU Gregorio Mara&#x000f1;&#x000f3;n, Madrid, Spain</aff><aff id="af3-copd-3-683"><label>3</label> Service of Pneumology, Hospital General Universitario de Guadalajara, Guadalajara, Spain</aff><aff id="af4-copd-3-683"><label>4</label> Respiratory Area, Medical Department, Boehringer Ingelheim Espa&#x000f1;a, Madrid, Spain</aff><author-notes><corresp id="c1-copd-3-683">Correspondence: Antonio Mart&#x000ed;n, Pfizer Spain, Avenida de Europa 20B, Parque Empresarial la Moraleja, E-28108, Alcobendas, Madrid, Spain, Tel +34 91 490 9628, Fax +34 91 490 9721, Email<email>antonio.martin@pfizer.com</email></corresp></author-notes><!--Dove Press titles changed from ppub to collections in 2009.								Fake epub written to satisfy Base Date Type=epub--><pub-date pub-type="ppub"><month>12</month><year>2008</year></pub-date><pub-date pub-type="epub"><month>12</month><year>2008</year></pub-date><volume>3</volume><issue>4</issue><fpage>683</fpage><lpage>692</lpage><copyright-statement>&#x000a9; 2008 Dove Medical Press Limited. All rights reserved</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Background</title><p>The objective of this study was to measure health-related quality of life (HRQL) in outpatients with chronic obstructive pulmonary disease (COPD) and to assess differences in HRQL according to age, gender, and severity of COPD.</p></sec><sec sec-type="methods"><title>Methods</title><p>A total of 9405 patients (79% men, mean age 68 years) participated in a cross-sectional study. HRQL was measured with the Short Form 12 Health Survey Questionnaire (SF-12). Severity of COPD was graded into three levels according to forced expiratory volume in one second value.</p></sec><sec><title>Results</title><p>COPD severity was mild in 33.8% of cases, moderate in 49.3% and severe in 16.8%. The mean physical component summary (PCS-12) and mental component summary (MCS-12) scores were 36.8 &#x000b1; 10.4 and 47.2 &#x000b1; 11.2, respectively. General health and physical functioning domains were those with the lowest scores. The mean MCS-12 scores were significantly higher in men (47.9 &#x000b1; 10.9) than in women (44.1 &#x000b1; 11.8) (<italic>P</italic> &#x0003c; 0.001). Patients older than 60 years rated HRQL worse than patients aged 40&#x02013;59 years. There were statistically significant differences according to severity of disease in the mean scores of all domains of the PCS-12 and MCS-12 scales.</p></sec><sec><title>Conclusions</title><p>The present findings show the influence of female gender, older age and moderate-to-severe of airflow limitation on HRQL in outpatients with COPD attended in daily practice.</p></sec></abstract><kwd-group><kwd>health status</kwd><kwd>health surveys</kwd><kwd>multicenter study</kwd><kwd>pulmonary disease</kwd><kwd>chronic obstructive/epidemiology</kwd><kwd>quality of life</kwd><kwd>questionnaires</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Chronic obstructive pulmonary disease (COPD) is a debilitating multicomponent respiratory condition primarily affecting the airway and lung parenchyma but also inducing a variety of extrapulmonary consequences, such as systemic inflammation, nutritional abnormalities, weight loss, skeletal muscle dysfunction and additional organ effects (<xref ref-type="bibr" rid="b12-copd-3-683">Decramer et al 2005</xref>). The high burden of COPD resulting from cough, sputum production and shortness of breath, is further contributed to by systemic effects, leading to a pronounced deterioration in health status and a diminished quality of life. It has been largely recognized that COPD is a public health problem worldwide and a major cause of chronic morbidity and mortality (<xref ref-type="bibr" rid="b10-copd-3-683">Chan-Yeung et al 2004</xref>; <xref ref-type="bibr" rid="b29-copd-3-683">Pauwels and Rabe 2004</xref>; <xref ref-type="bibr" rid="b25-copd-3-683">Manino 2005</xref>). COPD is a highly prevalent disease, and it is estimated that 7%&#x02013;10% of the adult population may be affected (<xref ref-type="bibr" rid="b33-copd-3-683">Sobradillo-Pe&#x000f1;a 2000</xref>; <xref ref-type="bibr" rid="b18-copd-3-683">Halbet et al 2003</xref>, <xref ref-type="bibr" rid="b19-copd-3-683">2006</xref>). In spite of antismoking campaigns, the prevalence and mortality rates of COPD continue to rise every year. It has been shown that COPD is the most rapidly increasing cause of death in individuals older than 65 years of age, which represents the most rapidly growing segment of the population in developed countries. Disability from COPD is expected to rise by 2020 with aging of the population and the increase in disease prevalence (<xref ref-type="bibr" rid="b39-copd-3-683">Weiss et al 2003</xref>).</p><p>Health-related quality of life (HRQL) in COPD patients has received an increasing interest over the past decade. An impaired health status is a risk factor for frequent exacerbations and hospital admissions (<xref ref-type="bibr" rid="b27-copd-3-683">Miravitlles et al 2006</xref>). Previous studies using both generic and disease-specific instruments for measuring HRQL in COPD patients (<xref ref-type="bibr" rid="b24-copd-3-683">Mahler 2000</xref>) have shown relationships between HRQL and disease severity, respiratory symptoms, gender, comorbidity, body weight, upper airway symptoms, and psychological status (<xref ref-type="bibr" rid="b17-copd-3-683">Hajiro et al 2000</xref>; <xref ref-type="bibr" rid="b40-copd-3-683">Wijnhoven et al 2003</xref>; <xref ref-type="bibr" rid="b30-copd-3-683">Peruzza et al 2003</xref>; <xref ref-type="bibr" rid="b21-copd-3-683">Hurst et al 2004</xref>; <xref ref-type="bibr" rid="b22-copd-3-683">Katsura et al 2005</xref>; <xref ref-type="bibr" rid="b34-copd-3-683">St&#x000e5;hl et al 2005</xref>; <xref ref-type="bibr" rid="b11-copd-3-683">de Torres et al 2006</xref>). In a recent study carried out in Spain, determinants of HRQL in patients with COPD followed in primary care included sex, forced expiratory volume in one second (FEV<sub>1</sub>), use of oxygen therapy, and number of visits to emergency rooms and hospital admissions (<xref ref-type="bibr" rid="b9-copd-3-683">Carrasco Garrido et al 2006</xref>).</p><p>In order to provide further information on HRQL in patients with COPD, a multicenter cross-sectional study was designed, the primary objectives of which were to collect information on HRQL in a large sample of outpatients with COPD visited by family physicians and pneumologists in actual conditions of the daily practice and to determine whether there were differences in HRQL according to age, gender, and severity of COPD. Secondary objectives included to assess the correlation between quality of life perceived by COPD patients and functional status (FEV<sub>1</sub>) and level of dyspnea, and to determine health care resources consumption.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study design</title><p>The <italic>VICE</italic> Study (Spanish acronym of <italic>Living with Chronic Obstructive Pulmonary Disease</italic>) was a 2-month (April&#x02013;May 2004) cross-sectional survey of the first five consecutive patients with COPD in the outpatient setting seen by general practitioners in primary care centers and pneumologists in the outpatients clinics of the Services of Pneumology of acute care hospitals from all over Spain. A sample of 2300 general practitioners and 200 pneumologists were recruited using a stratified random sample drawn from the list of registered physicians in all autonomous communities. Physicians were eligible for inclusion if they were actively practicing in Spain, reported spending at least 50% of their time in direct patient care and had a primary specialty in family practice or pneumology. Physicians participated voluntarily in the study and did not receive any payment.</p><p>The study protocol was approved by the Ethics Committee of hospital Gregorio Mara&#x000f1;&#x000f3;n, Madrid (Spain), and written informed consent was obtained from all participants.</p></sec><sec><title>Patients</title><p>Patients of both sexes, aged 40 years or older, with a previous diagnosis of COPD (confirmed by history and spirometry) were eligible provided that the reason of consultation was related to his/her pulmonary condition. The diagnosis of the disease was performed according to the criteria of the Spanish Society of Pneumology and Chest Surgery (SEPAR) based on the demonstration, through a forced spirometry, of a FEV<sub>1</sub> below 80% of the reference value and a FEV<sub>1</sub>/forced vital capacity (FVC) ratio below 0.7 after the bronchodilation test. The severity of COPD was graded according to the FEV<sub>1</sub> value: mild (FEV<sub>1</sub> 60%&#x02013;80% of the reference value), moderate (FEV<sub>1</sub> 40%&#x02013;59% of the reference value) and severe (FEV<sub>1</sub> &#x0003c; 40% of the reference value) following SEPAR criteria (<xref ref-type="bibr" rid="b4-copd-3-683">Barber&#x000e0; et al 2001</xref>), which are based on the guidelines of the British Thoracic Society (<xref ref-type="bibr" rid="b6-copd-3-683">BTS 1997</xref>). Spirometric measurements at the time of the study were not performed.</p><p>Patients with an acute worsening of their COPD in the previous month were excluded as were those suffering from any physical and/or psychiatric disease precluding to complete the HRQL questionnaire. Patients with more than 80% of missing data for the study variables in their medical records were also excluded.</p></sec><sec><title>Data collection</title><p>Interviews were carried out by the participating physician during the course of the patient&#x02019;s consultation in routine daily practice. All data were collected in a single visit using a questionnaire in which the following variables were recorded: age; sex; height; weight; smoking habit (current smoker, never smoker, ex-smoker); year of COPD diagnosis; data of the last spirometric measurement and FEV<sub>1</sub> and FEV<sub>1</sub>/FVC values; severity of COPD; current COPD therapy including nonpharmacological management (smoking cessation counseling, stop smoking treatment, oxygen therapy, rehabilitation, others) and pharmacological treatment (short-acting &#x003b2;<sub>2</sub>-agonists, long-acting &#x003b2;<sub>2</sub>-agonists, short-acting anticholinergics, long-acting anticholinergics, inhaled steroids, oral steroids, a fixed combination of anticholinergics and short-acting &#x003b2;<sub>2</sub>-agonists, a fixed combination of long-acting &#x003b2;<sub>2</sub>-agonists and inhaled steroids, antibiotics, others); disability; and health resources utilization in the previous 12 months (number of outpatient visits to either the primary care physician and the pneumologist, emergency department visits, hospitalizations, and days on sick leave).</p><p>Disability was classified according to the Medical Research Council (MRS) dyspnea scale (<xref ref-type="bibr" rid="b5-copd-3-683">Bestall et al 1999</xref>). The MRC dyspnea scale concerns perceived breathlessness and consists of five degrees: 1, &#x0201c;shortness of breath with strenuous exercise&#x0201d;; 2, &#x0201c;shortness of breath when hurrying&#x0201d;; 3, &#x0201c;walking slower than people of the same age on the level ground or stop for breath while walking at own pace on the level ground&#x0201d;; 4, &#x0201c;needing to stop after 100 yards on the level ground&#x0201d;; 5, &#x0201c;too breathless to leave the house&#x0201d;. A Spanish translation of MRC dyspnea scale was administered to the subjects (<xref ref-type="bibr" rid="b15-copd-3-683">Gallego et al 2002</xref>).</p></sec><sec><title>Health status</title><p>All patients were administered the Short Form 12 Health Survey Questionnaire (SF-12), an abbreviated version of the SF-36 health questionnaire that contains 12 items (<xref ref-type="bibr" rid="b38-copd-3-683">Ware et al 1996</xref>). These 12 items explain more than 90% of the variance of the physical and mental component scales of the SF-36. From them two scores can be calculated, the physical (PCS-12) and the mental (PCS-12) component summary, using a value of 50 with a standard deviation of 10 as reference population. In this study, the general Spanish adult population has been used as reference (<xref ref-type="bibr" rid="b1-copd-3-683">Alonso et al 1998a</xref>; <xref ref-type="bibr" rid="b36-copd-3-683">Vilagut et al 2005</xref>). Scores range from 0 to 100, with higher scores representing better HRQL. A score &#x0003e;60 has been regarded as high HRQL, 40&#x02013;60 as normal HRQL, and &#x0003c;40 as impaired (low) HRQL. A translated version of the questionnaire validated for Spain has been used (<xref ref-type="bibr" rid="b2-copd-3-683">Alonso et al 1998b</xref>).</p></sec><sec><title>Statistical analysis</title><p>In order to detect a clinically relevant differences of 5 points in the mean PCS-12 and MCS-12 scores among the subgroups of men and women stratified by the three severity levels of COPD with a statistical power of 95% and a level of statistical significance (alpha) of 0.05, using a two-tailed Student&#x02019;s <italic>t</italic> test for the comparison of two groups (considering a standard deviation of 12 for the mean SF-12 scores of each group), a total number of patients required in each stratum was 165. According to data of the IBERPOC study (<xref ref-type="bibr" rid="b32-copd-3-683">Sobradillo et al 1999</xref>; <xref ref-type="bibr" rid="b37-copd-3-683">Villasante Fernandez-Montes et al 1999</xref>), women showed the lowest prevalence of COPD (22%) with the subset of women with severe disease accounting for 1.653% of the total number of patients with COPD. Therefore, the total number of patients required was 9981 (165/0.01653). This number was increased to 12,477 assuming losses of patients due to nonevaluable cases of 20%.</p><p>The Statistical Package for the Social Sciences (version 12.0; SPSS Inc., Chicago, IL) was used for the analysis of data. Double data entry was carried out with a subsequent validation to guarantee the quality and consistency of the data. Continuous variables are expressed as mean and standard deviation (SD) or median and ranges (25th&#x02013;75th percentiles). Qualitative variables are described as frequency and percentages. Confidence intervals (CIs) were calculated at the 95% level. Differences of HRQL in the subgroups of patients according to gender and severity of COPD were analyzed with the paired Student&#x02019;s <italic>t</italic> test. The Spearman&#x02019;s rank-order correlation coefficient (&#x003c1;) was calculated to assess the relationship between HRQL and FEV<sub>1</sub> and level of dyspnea. The chi-square (&#x003c7;<sup>2</sup>) test was used to assess differences in health resources utilization among the study groups. Statistical significance was set at <italic>P</italic> &#x02264; 0.05.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The number of physicians participating in the study was 2144 (general practitioners, n = 1826; pneumologists, n = 240), which enabled a recruitment total of 10,782 patients. However, 1377 patients (12.8%) were excluded due to missing data in the patient&#x02019;s medical history (n = 831) and lack of fulfillment of the selection criteria (n = 546).</p><p>The study population included 9405 patients (79.7% men, 20.3% women) with a mean (&#x000b1;SD) age of 67.8 &#x000b1; 9.8 years. Sociodemographic and clinical characteristics of the patients are shown in <xref ref-type="table" rid="t1-copd-3-683">Table 1</xref>. Salient features were as follows: 69% of patients were found in the 60&#x02013;79 year stratum, 77% had a body mass index (BMI) &#x02265; 25 kg/m<sup>2</sup>, 61% were ex-smokers (median of 10 years since smoking cessation) and 22.6% were current smokers (median pack-years 40) and had been smoking for a mean of 36.7 &#x000b1; 13.6 years. Patients had a long-standing COPD, with a mean time since diagnosis of 10 years.</p><p>With regard to the last spirometric measurement, the mean FEV<sub>1</sub> value was 55.1 &#x000b1; 14.3%. The severity of disease was mild in 33.8% of cases, moderate in 49.3% and severe in 16.8%. There were differences in COPD severity according to gender, with significantly higher percentages of men compared to women with moderate (50.4% vs 45.4%) and severe (18.0% vs 10.7%) disease (<italic>P</italic> &#x0003c; 0.001). 40.8% of patients aged 40&#x02013;50 years suffered from moderate or severe COPD as opposed to 76.1% of patients of 80 years of age or older (<italic>P</italic> &#x0003c; 0.001). Most patients (46%) had a moderate degree of dyspnea (MRC category 2). However, 14.5% of men showed a moderately severe degree of dyspnea (MRC categories 4 and 5) compared with 13.7% of women. The degree of dyspnea also increased with age, with 3.4% of patients aged 40&#x02013;50 years in the MRC categories 4 and 5 compared with 29.2% of patients aged 80 years or older (<italic>P</italic> &#x0003c; 0.001).</p><p>The mean PCS-12 and MCS-12 scores were 36.8 &#x000b1; 10.4 and 47.2 &#x000b1; 11.2, respectively. General health and physical functioning domains were those with the lowest scores, whereas role emotional and social functioning domains were those with the highest scores (<xref ref-type="table" rid="t2-copd-3-683">Table 2</xref>). According to results of the SF-12 questionnaire, HRQL was graded as normal (40&#x02013;60 points) by 61% of patients and low (&#x0003c;40 points) by 39% of patients. However, a higher percentage of patients scored less than 40 points in the physical health domain compared with the mental health domain (60.2% vs 25.7%) (<xref ref-type="table" rid="t2-copd-3-683">Table 2</xref>). As compared to the reference population, patients with COPD had a reduction of HRQL, with a mean of &#x02212;1.32 &#x000b1; 1.04 for PCS-12 and &#x02212;0.28 &#x000b1; 1.12 for MCS-12.</p><p>When HRQL in men and women was compared, there were no significant differences in the mean PCS-12 scores (36.9 &#x000b1; 10.4 vs 36.5 &#x000b1; 10.3) but the mean MCS-12 scores were significantly higher in men (47.9 &#x000b1; 10.9) than in women (44.1 &#x000b1; 11.8) (<italic>P</italic> &#x0003c; 0.001). Scores for the different domains of PCS-12 and MSC-12 according to gender are shown in <xref ref-type="fig" rid="f1-copd-3-683">Figure 1</xref>. As compared with the reference population, the mean reduction of HRQL for the mental domain was significantly higher in women (&#x02212;0.59 &#x000b1; 1.18) than in men (&#x02212;0.20 &#x000b1; 1.09) (<italic>P</italic> &#x0003c; 0.001).</p><p>As shown in <xref ref-type="table" rid="t3-copd-3-683">Table 3</xref>, the physical domain was scored &#x0003c;40 points by a significantly higher percentage of patients compared with the mental domain for all age strata. On the other hand, the percentage of patients considering that their HRQL in the physical domain was normal or high was also significantly lower than for the mental domain. Patients older than 60 years of age rated HRQL worse than patients in the 40&#x02013;59 year age group.</p><p>In relation to COPD severity, a significantly higher percentage of patients with mild disease rated HRQL as normal compared with patients with severe disease (physical domain 61.3% vs 18.5%; mental domain 75.9% vs 53.5%; <italic>P</italic> &#x0003c; 0.001) (<xref ref-type="table" rid="t3-copd-3-683">Table 3</xref>). The mean PCS-12 scores were 42.4 &#x000b1; 9.5 in patients with mild disease, 35.2 &#x000b1; 9.5 in those with moderate COPD and 30.6 &#x000b1; 9.5 in those with severe disease (P &#x0003c; 0.001); the corresponding figures for the mean MCS-12 scores were 49.1 &#x000b1; 10.1, 47.0 &#x000b1; 11.1 and 43.9 &#x000b1; 13.0 in the groups of mild, moderate and severe COPD, respectively. There were statistically significant differences according to severity of disease in the mean scores of all domains of the PCS-12 and MCS-12 scales (<xref ref-type="fig" rid="f2-copd-3-683">Figure 2</xref>). Moreover, patients with severe COPD showed a significantly higher reduction of HRQL for both the physical (&#x02212;1.94 &#x000b1; 0.95) and mental domains (&#x02212;0.61 &#x000b1; 1.30) than patients with moderate or mild COPD as compared with the reference population.</p><p>HRQL correlated significantly with FEV<sub>1</sub> in both PCS-12 (&#x003c1; = 0.313, <italic>P</italic> &#x0003c; 0.001) and MCS-12 (&#x003c1; = 0.101, <italic>P</italic> &#x0003c; 0.001) scales. As expected, an inverse significant correlation between HRQL and degree of dyspnea in the PCS-12 (&#x003c1; = &#x02212;0.599, <italic>P</italic> &#x0003c; 0.001) and the MCS-12 (&#x003c1; = &#x02212;0.237, <italic>P</italic> &#x0003c; 0.001) scales was observed.</p><p>In relation to utilization of health resources, patients with severe COPD had more visits to the primary care center in the previous 12 months than those with mild to moderate COPD (5.8, 4.6 and 3.2, respectively, <italic>P</italic> &#x0003c; 0.001). They were also in the emergency department more often (2.5, 1.6 and 0.9, respectively, <italic>P</italic> &#x0003c; 0.001). Patients with severe COPD had longer hospital stays (16.7 days) when compared to those with moderate (10.9 days) or mild disease (8.8 days) (<italic>P</italic> &#x0003c; 0.001) as well as a more days on sick leave (51.2, 29.4 and 18.9, respectively, <italic>P</italic> &#x0003c; 0.001).</p><p>Details of nonpharmacological and pharmacological treatment according to HRQL and severity of COPD are summarized in <xref ref-type="table" rid="t4-copd-3-683">Table 4</xref>. Anti-smoking treatment was recorded ino nly 4% of patients, and even in a lower percentage of patients (3.6%) with severe COPD. More than 80% of patients were receiving pharmacological treatment (bronchodilators in 73.7%, fixed combinations in 57.5% and steroids in 19.8%). Long-acting &#x003b2;<sub>2</sub>-agonists were given to 42% of patients. When patients were stratified according to normal or low HRQL, a significantly higher percentage of patients with low HRQL received any modality of pharmacological treatment except for long-acting anticholinergics. In addition, a significantly higher percentage of patients with severe COPD received any of medication as compared with those with mild and moderate severity of disease.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The use of HRQL measures in COPD has currently achieved widespread acceptance (<xref ref-type="bibr" rid="b13-copd-3-683">Domingo-Salvany et al 2002</xref>). However, HRQL measures have shown an inconsistent relationship with clinical and functional components of the disease. The objective of this study was to assess HRQL in a large population of COPD patients during the patients&#x02019; routine care in the outpatient setting. A generic quality of life questionnaire, the SF-12 that enables to calculate the physical well-being and the mental-well being components of HRQL was administered to all patients. This instrument has been shown to be a valid evaluation tool with excellent measurement properties in patients with chronic respiratory conditions, such as COPD and asthma (Katz et al 2000; <xref ref-type="bibr" rid="b16-copd-3-683">Garratt et al 2000</xref>; <xref ref-type="bibr" rid="b26-copd-3-683">Miravitlles et al 2002</xref>, <xref ref-type="bibr" rid="b28-copd-3-683">2004</xref>).</p><p>In general, most patients perceived that their HRQL was not impaired by COPD, although the physical health domain was rated poorly than the mental health domain, with general health, physical functioning, role physical and vitality showing lowers scores than the domains of mental health, emotional role, social functioning and bodily pain. Lower scores for the PCS-12 component than for the MSC-12 component in patients with COPD have been also reported by others (<xref ref-type="bibr" rid="b34-copd-3-683">St&#x000e5;hl et al 2005</xref>;<xref ref-type="bibr" rid="b9-copd-3-683">Carrasco Garrido et al 2006</xref>).</p><p>In agreement with previous reports (<xref ref-type="bibr" rid="b30-copd-3-683">Peruzza et al 2003</xref>; <xref ref-type="bibr" rid="b11-copd-3-683">de Torres et al 2006</xref>; <xref ref-type="bibr" rid="b9-copd-3-683">Carrasco Garrido et al 2006</xref>), the present findings confirm the effect of age, gender and stage of disease on HRQL in patients with COPD. It has been shown that COPD is a main cause of severe deterioration of quality of life in elderly subjects and that the degree of this impairment mainly depends on the severity of airway obstruction (<xref ref-type="bibr" rid="b30-copd-3-683">Peruzza et al 2003</xref>). In our study, patients older than 60 years of age, particularly those in the 70&#x02013;79-year-old group, perceived that their HRQL was more affected by COPD than younger patients. However, in the age stratum of very old patients (&#x02265;80 years), a lower percentage of subjects considered that their quality of life for the physical and mental health domains was low as compared with patients aged 70 to 79 years. This observation may be related to that fact that the oldest elderly population tend to restrict their own daily activities and expectations.</p><p>Compared with men, women had worse scores in all domains of mental health and in the role of physical and bodily pain of the physical health domain. Taking into account that a significantly percentage of men had moderate and severe COPD, this observation is clinically relevant as indicating that women with COPD develop symptoms influencing HRQL with less degree of obstruction than men. Unfortunately, a better characterization of our female population is not feasible given that other factors, such as socioeconomic status, education level, working status or co-morbidity were not evaluated. However, our results are in-line with those reported by <xref ref-type="bibr" rid="b11-copd-3-683">de Torres and colleagues (2006)</xref> in a FEV<sub>1</sub>-matched case series study of 73 consecutive women and 73 men. These authors speculate that the factors affecting HRQL differ by gender at least in early stages of the disease and that the perceived expression of the disease is different between genders. In the study of <xref ref-type="bibr" rid="b3-copd-3-683">Antonelli-Incalzi and colleagues (2003)</xref> in which differences in health status according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria was evaluated, female sex was also associated with a greater impact of COPD on the health status.</p><p>In our study, like others (<xref ref-type="bibr" rid="b14-copd-3-683">Ferrer et al 1997</xref>; <xref ref-type="bibr" rid="b17-copd-3-683">Hajiro et al 2000</xref>) disease severity (based on FEV<sub>1</sub>) influenced significantly HRQL among subjects with COPD. Therefore, staging criteria for COPD based on percentage of predicted FEV<sub>1</sub> separated groups of patients with varying degrees of impairment in HRQL. Contrary to expectations, even patients with mild disease showed substantially compromised HRQL. Additionally, the importance of dyspnea causing patients with COPD to reduce their activities of daily living (<xref ref-type="bibr" rid="b31-copd-3-683">Reardon et al 2006</xref>) is also demonstrated in our study, with dyspnea showing a stronger correlation with HRQL than FEV<sub>1</sub>.</p><p>A remarkable finding was that 22.6% of COPD patients were current smokers but only 4% of the total population was receiving smoking cessation treatment. In a survey of 11,973 COPD patients carried out in Spain, 35% of them continued smoking (<xref ref-type="bibr" rid="b35-copd-3-683">Viejo-Ba&#x000f1;uelos et al 2006</xref>). Our patients had been smoking for about 40 years and the median pack-years was 40. Effective intervention strategies directed to quit smoking in COPD patients are mandatory. With regard to pharmacological treatment, bronchodilators, fixed combinations and steroids were the most frequently used medications. Anticholinergics were used by 58.5% of the patients followed by &#x003b2;<sub>2</sub>-agonists (50%), theophylline (21.4%), inhaled steroids (15.9%) and oral steroids (7.5%). High dose inhaled corticosteroids in patients with moderate to severe chronic obstructive pulmonary disease has been associated with a reduced rate of decline in health status (<xref ref-type="bibr" rid="b8-copd-3-683">Burge et al 2000</xref>). Finally, we also found a strong relationship between health-care resource utilization and severity of disease (<xref ref-type="bibr" rid="b20-copd-3-683">Hilleman et al 2000</xref>).</p><p>Our study had some limitations. A generic questionnaire was used to measure HRQL, which is less sensitive than the specific tools. The cross-sectional design of the study limits our ability to describe how progression of disease stage relates to changes in HRQL. Patients were recruited from those visited in the outpatient setting, mostly in primary care centers, and therefore may not represent the COPD population at large. It should be noted that 16% of our population were never smokers. These patients were not excluded because the objective of the study was to assess HRQL in outpatients with COPD attended by family physicians and pneumologists in actual conditions of the daily practice. However, a diagnosis other than COPD cannot be excluded. In a recent multicenter study carried out in 9425 subjects with COPD recruited at 12 different sites worldwide, the percentage of never smokers varied between 3.1% and 9.4% in men and between 2.9% and 11.2% in women (<xref ref-type="bibr" rid="b7-copd-3-683">Buist et al 2007</xref>). On the other hand, other factors that may affect HRQL (eg, co-morbidity) were not evaluated. However, the large sample size strengths the findings of our study.</p><p>In summary, this study shows the influence of female gender, older age and moderate-to-severe of airflow limitation on HRQL, particularly on the physical component of the SF-12 instrument, in patients with COPD attended in the outpatient setting in daily practice conditions.</p></sec></body><back><ack><title>Acknowledgements</title><p>Presented in part as poster presentation at the Annual Congress of the European Respiratory Society, Munich, Germany, September 2&#x02013;6, 2006. The authors are indebted to members of the <italic>VICE</italic> Study for the recruitment of patients, to Immaculada Vilardaga, Euroclin Institute, Barcelona, for his contribution to the statistical analysis and to Marta Pulido, MD, for editing the manuscript and editorial assistance.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>A Mart&#x000ed;n is employed by Pfizer, Madrid, Spain. E Gobartt is employed by Boehringer Ingelheim Espa&#x000f1;a, Madrid, Spain. JM Rodr&#x000ed;guez, JL Izquierdo, and P de Lucas have no conflicts of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>J</given-names></name><name><surname>Prieto</surname><given-names>L</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><etal/></person-group><year>1998a</year><article-title>Testing the measurement properties of the Spanish version of the SF-36 Health Survey among male patients with chronic obstructive pulmonary disease. Quality of Life in COPD Study Group</article-title><source>J Clin Epidemiol</source><volume>51</volume><fpage>1087</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">9817126</pub-id></citation></ref><ref id="b2-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>J</given-names></name><name><surname>Regidor</surname><given-names>E</given-names></name><name><surname>Barrio</surname><given-names>G</given-names></name><etal/></person-group><year>1998b</year><article-title>[Population reference values of the Spanish version of the Health Questionnaire SF-36</article-title><source>] Med Clin (Barc)</source><volume>111</volume><fpage>410</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9834913</pub-id></citation></ref><ref id="b3-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antonelli-Incalzi</surname><given-names>R</given-names></name><name><surname>Imperiale</surname><given-names>C</given-names></name><name><surname>Bellia</surname><given-names>V</given-names></name><etal/></person-group><collab>the SaRA investigators</collab><year>2003</year><article-title>Do GOLD stages of COPD severity really correspond to differences in health status?</article-title><source>Eur Respir J</source><volume>22</volume><fpage>444</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14516133</pub-id></citation></ref><ref id="b4-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barber&#x000e0;</surname><given-names>JA</given-names></name><name><surname>Peces-Barba</surname><given-names>G</given-names></name><name><surname>Agust&#x000ed;</surname><given-names>AGN</given-names></name><etal/></person-group><year>2001</year><article-title>Sociedad Espa&#x000f1;ola de Neumolog&#x000ed;a y Cirug&#x000ed;a Tor&#x000e1;cica (SEPAR): Gu&#x000ed;a para el diagn&#x000f3;sticoy tratamiento de la enfermedad pulmonar obstructiva cr&#x000f3;nica</article-title><source>Arch Bronconeumol</source><volume>37</volume><fpage>297</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">11412529</pub-id></citation></ref><ref id="b5-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bestall</surname><given-names>JC</given-names></name><name><surname>Paul</surname><given-names>EA</given-names></name><name><surname>Garrod</surname><given-names>R</given-names></name><etal/></person-group><year>1999</year><article-title>Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease</article-title><source>Thorax</source><volume>54</volume><fpage>581</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10377201</pub-id></citation></ref><ref id="b6-copd-3-683"><citation citation-type="journal"><collab>[BTS] British Thoracic Society</collab><year>1997</year><article-title>BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS</article-title><source>Thorax</source><volume>52</volume><issue>Suppl 5</issue><fpage>S1</fpage><lpage>S28</lpage></citation></ref><ref id="b7-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buist</surname><given-names>AS</given-names></name><name><surname>McBurnie</surname><given-names>MA</given-names></name><name><surname>Vollmer</surname><given-names>WM</given-names></name><etal/></person-group><collab>on behalf of the BOLD Collaborative Research Group</collab><year>2007</year><article-title>International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study</article-title><source>Lancet</source><volume>370</volume><fpage>741</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17765523</pub-id></citation></ref><ref id="b8-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burge</surname><given-names>PS</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><etal/></person-group><year>2000</year><article-title>Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial</article-title><source>BMJ</source><volume>320</volume><fpage>1297</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">10807619</pub-id></citation></ref><ref id="b9-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carrasco Garrido</surname><given-names>P</given-names></name><name><surname>de Miguel D&#x000ed;ez</surname><given-names>J</given-names></name><name><surname>Rejas Guti&#x000e9;rrez</surname><given-names>J</given-names></name><etal/></person-group><year>2006</year><article-title>Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study</article-title><source>Health Qual Life Outcomes</source><volume>4</volume><fpage>31</fpage><pub-id pub-id-type="pmid">16719899</pub-id></citation></ref><ref id="b10-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan-Yeung</surname><given-names>M</given-names></name><name><surname>Ait-Khaled</surname><given-names>N</given-names></name><name><surname>White</surname><given-names>N</given-names></name><etal/></person-group><year>2004</year><article-title>The burden and impact of COPD in Asia and Africa</article-title><source>Int J Tuberc Lung Dis</source><volume>8</volume><fpage>2</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">14974740</pub-id></citation></ref><ref id="b11-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Torres</surname><given-names>JP</given-names></name><name><surname>Casanova</surname><given-names>C</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>C</given-names></name><etal/></person-group><year>2006</year><article-title>Gender associated differences in determinants of quality of life in patients with COPD: a case series study</article-title><source>Health Qual Life Outcomes</source><volume>4</volume><fpage>72</fpage><pub-id pub-id-type="pmid">17007639</pub-id></citation></ref><ref id="b12-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>De Benedetto</surname><given-names>F</given-names></name><name><surname>Del Ponte</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Systemic effects of COPD</article-title><source>Respir Med</source><volume>99</volume><fpage>S3</fpage><lpage>S10</lpage><pub-id pub-id-type="pmid">16219454</pub-id></citation></ref><ref id="b13-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Domingo-Salvany</surname><given-names>A</given-names></name><name><surname>Lamarca</surname><given-names>R</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><etal/></person-group><year>2002</year><article-title>Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><volume>166</volume><fpage>680</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12204865</pub-id></citation></ref><ref id="b14-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Alonso</surname><given-names>J</given-names></name><name><surname>Morera</surname><given-names>J</given-names></name><etal/></person-group><year>1997</year><article-title>Chronic obstructive pulmonary disease stage and health-related quality of life</article-title><source>Ann Intern Med</source><volume>127</volume><fpage>1072</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9412309</pub-id></citation></ref><ref id="b15-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallego</surname><given-names>MC</given-names></name><name><surname>Samaniego</surname><given-names>J</given-names></name><name><surname>Alonso</surname><given-names>J</given-names></name><etal/></person-group><year>2002</year><article-title>[Dyspnea in COPD: relation to the MRC scale with dyspnea induced by walking and cardiopulmonary stress testing</article-title><source>] Arch Bronconeumol</source><volume>38</volume><fpage>112</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11900687</pub-id></citation></ref><ref id="b16-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garratt</surname><given-names>AM</given-names></name><name><surname>Hutchinson</surname><given-names>A</given-names></name><name><surname>Russell</surname><given-names>I</given-names></name></person-group><year>2000</year><article-title>Patient-assessed measures of health outcome in asthma: A comparison of four approaches</article-title><source>Respir Med</source><volume>94</volume><fpage>597</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">10921766</pub-id></citation></ref><ref id="b17-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hajiro</surname><given-names>T</given-names></name><name><surname>Nishimura</surname><given-names>K</given-names></name><name><surname>Tsukino</surname><given-names>M</given-names></name><etal/></person-group><year>2000</year><article-title>Stages of disease severity and factors that affect the health status of patients with chronic obstructive pulmonary disease</article-title><source>Respir Med</source><volume>94</volume><fpage>841</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11001074</pub-id></citation></ref><ref id="b18-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halbert</surname><given-names>RJ</given-names></name><name><surname>Isonaka</surname><given-names>S</given-names></name><name><surname>George</surname><given-names>D</given-names></name><etal/></person-group><year>2003</year><article-title>Interpreting COPD prevalence estimates: what is the true burden of disease?</article-title><source>Chest</source><volume>123</volume><fpage>1684</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">12740290</pub-id></citation></ref><ref id="b19-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halbert</surname><given-names>RJ</given-names></name><name><surname>Natoli</surname><given-names>JL</given-names></name><name><surname>Gano</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Global burden of COPD: systematic review and meta-analysis</article-title><source>Eur Respir J</source><volume>28</volume><fpage>523</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">16611654</pub-id></citation></ref><ref id="b20-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hilleman</surname><given-names>DE</given-names></name><name><surname>Dewan</surname><given-names>N</given-names></name><name><surname>Malesker</surname><given-names>M</given-names></name><etal/></person-group><year>2000</year><article-title>Pharmacoeconomic evaluation of COPD</article-title><source>Chest</source><volume>118</volume><fpage>1278</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">11083675</pub-id></citation></ref><ref id="b21-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>JR</given-names></name><name><surname>Wilkinson</surname><given-names>TMA</given-names></name><name><surname>Donaldson</surname><given-names>GC</given-names></name><etal/></person-group><year>2004</year><article-title>Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD)</article-title><source>Respir Med</source><volume>98</volume><fpage>767</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">15303642</pub-id></citation></ref><ref id="b22-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katsura</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Kida</surname><given-names>K</given-names></name></person-group><year>2005</year><article-title>Both generic and disease specific health-related quality of life are deteriorated in patients with underweight COPD</article-title><source>Respir Med</source><volume>99</volume><fpage>624</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15823461</pub-id></citation></ref><ref id="b23-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>PP</given-names></name><name><surname>Eisner</surname><given-names>MD</given-names></name><name><surname>Yelin</surname><given-names>EH</given-names></name><etal/></person-group><year>2005</year><article-title>Functioning and psychological status among individuals with COPD</article-title><source>Qual Life Res</source><volume>14</volume><fpage>1835</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16155771</pub-id></citation></ref><ref id="b24-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahler</surname><given-names>DA</given-names></name></person-group><year>2000</year><article-title>How should health-related quality f life be assessed in patients with COPD?</article-title><source>Chest</source><volume>117</volume><fpage>54S</fpage><lpage>57S</lpage><pub-id pub-id-type="pmid">10673476</pub-id></citation></ref><ref id="b25-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manino</surname><given-names>DM</given-names></name></person-group><year>2005</year><article-title>Epidemiology and global impact of chronic obstructive pulmonary disease</article-title><source>Semin Respir Crit Care Med</source><volume>26</volume><fpage>204</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">16088437</pub-id></citation></ref><ref id="b26-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Alvarez-Sala</surname><given-names>JL</given-names></name><name><surname>Lamarca</surname><given-names>R</given-names></name><etal/></person-group><collab>IMPAC Study Group</collab><year>2002</year><article-title>Treatment and quality of life in patients with chronic obstructive pulmonary disease</article-title><source>Qual Life Res</source><volume>11</volume><fpage>329</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">12086118</pub-id></citation></ref><ref id="b27-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Calle</surname><given-names>M</given-names></name><name><surname>Alvarez-Gutierrez</surname><given-names>F</given-names></name><etal/></person-group><year>2006</year><article-title>Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease</article-title><source>Qual Life Res</source><volume>15</volume><fpage>471</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16547786</pub-id></citation></ref><ref id="b28-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Pont</surname><given-names>A</given-names></name><etal/></person-group><collab>IMPAC Study Group</collab><year>2004</year><article-title>Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study</article-title><source>Thorax</source><volume>59</volume><fpage>387</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">15115864</pub-id></citation></ref><ref id="b29-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name></person-group><year>2004</year><article-title>Burden and clinical features of chronic obstructive pulmonary disease (COPD)</article-title><source>Lancet</source><volume>364</volume><fpage>613</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15313363</pub-id></citation></ref><ref id="b30-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peruzza</surname><given-names>S</given-names></name><name><surname>Sergi</surname><given-names>G</given-names></name><name><surname>Vianello</surname><given-names>A</given-names></name><etal/></person-group><year>2003</year><article-title>Chronic obstructive pulmonary disease (COPD) in elderly subjects: impact on functional status and quality of life</article-title><source>Respir Med</source><volume>97</volume><fpage>612</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12814144</pub-id></citation></ref><ref id="b31-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reardon</surname><given-names>JZ</given-names></name><name><surname>Lareau</surname><given-names>SC</given-names></name><name><surname>ZuWallack</surname><given-names>R</given-names></name></person-group><year>2006</year><article-title>Functional status and quality of life in chronic obstructive pulmonary disease</article-title><source>Am J Med</source><volume>119</volume><issue>10 Suppl 1</issue><fpage>32</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16996897</pub-id></citation></ref><ref id="b32-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sobradillo</surname><given-names>V</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Jimenez</surname><given-names>CA</given-names></name><etal/></person-group><year>1999</year><article-title>[Epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): prevalence of chronic respiratory symptoms and airflow limitation</article-title><source>] Arch Bronconeumol</source><volume>35</volume><fpage>159</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">10330536</pub-id></citation></ref><ref id="b33-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sobradillo-Pe&#x000f1;a</surname><given-names>S</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Gabriel</surname><given-names>R</given-names></name><etal/></person-group><year>2000</year><article-title>Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study</article-title><source>Chest</source><volume>118</volume><fpage>981</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11035667</pub-id></citation></ref><ref id="b34-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>St&#x000e5;hl</surname><given-names>E</given-names></name><name><surname>Lindberg</surname><given-names>A</given-names></name><name><surname>Jansson</surname><given-names>SA</given-names></name><etal/></person-group><year>2005</year><article-title>Health-related quality of life is related to COPD disease severity</article-title><source>Health Qual Life Outcomes</source><volume>3</volume><fpage>56</fpage><pub-id pub-id-type="pmid">16153294</pub-id></citation></ref><ref id="b35-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viejo-Ba&#x000f1;uelos</surname><given-names>JL</given-names></name><name><surname>Pueyo-Bastida</surname><given-names>A</given-names></name><name><surname>Fueyo-Rodr&#x000ed;guez</surname><given-names>A</given-names></name></person-group><year>2006</year><article-title>Characteristics of outpatients with CPD in daily practice: The E4 Spanish Project</article-title><source>Respir Med</source><volume>100</volume><fpage>2137</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16831541</pub-id></citation></ref><ref id="b36-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vilagut</surname><given-names>G</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Rajmil</surname><given-names>L</given-names></name><etal/></person-group><year>2005</year><article-title>[The Spanish version of the Short Form 36 Health Survey: a decade of experience and new developments</article-title><source>] Gat Sanit</source><volume>19</volume><fpage>135</fpage><lpage>50</lpage></citation></ref><ref id="b37-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villasante Fernandez-Montes</surname><given-names>C</given-names></name></person-group><year>1999</year><article-title>[IBERPOC: an evaluation of the results. The Scientific Committee of the IBERPOC Study</article-title><source>] Arch Bronconeumol</source><volume>35</volume><issue>Suppl 3</issue><fpage>40</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10410223</pub-id></citation></ref><ref id="b38-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>SD</given-names></name></person-group><year>1996</year><article-title>A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity</article-title><source>Med Care</source><volume>34</volume><fpage>220</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">8628042</pub-id></citation></ref><ref id="b39-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>DeMeo</surname><given-names>DL</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name></person-group><year>2003</year><article-title>COPD: problems in diagnosis and measurement</article-title><source>Eur Respir J</source><volume>21</volume><issue>Suppl 41</issue><fpage>4s</fpage><lpage>12s</lpage></citation></ref><ref id="b40-copd-3-683"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wijnhoven</surname><given-names>HAH</given-names></name><name><surname>Kriegsman</surname><given-names>DMW</given-names></name><name><surname>Hesselink</surname><given-names>AE</given-names></name><etal/></person-group><year>2003</year><article-title>The influence of co-morbidity on health-related quality of life in asthma and COPD patients</article-title><source>Respir Med</source><volume>97</volume><fpage>468</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">12735662</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="f1-copd-3-683" position="float"><label>Figure 1</label><caption><p>Mean scores of the physical component summary (PCS-12) (upper panel) and the mental component summary (MCS-12) (lower panel) in COPD patients according to gender (<sup>*</sup>statistically significant differences, P &#x0003c; 0.001).</p></caption><graphic xlink:href="copd-3-683f1"/></fig><fig id="f2-copd-3-683" position="float"><label>Figure 2</label><caption><p>Mean scores of the physical component summary (PCS-12) (upper panel) and the mental component summary (MCS-12) (lower panel) in COPD patients according to severity of disease (<italic>P</italic> &#x0003c; 0.001 in all domains of both components).</p></caption><graphic xlink:href="copd-3-683f2"/></fig><table-wrap id="t1-copd-3-683" position="float"><label>Table 1</label><caption><p>Sociodemographic and clinical characteristics of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">Number (%)</th><th align="left" rowspan="1" colspan="1">Mean &#x000b1; SD (range)<xref ref-type="table-fn" rid="tfn2-copd-3-683">*</xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total no of patients</td><td align="left" rowspan="1" colspan="1">9405</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age, years (n = 9095)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">67.8 &#x000b1; 9.8 (61&#x02013;75)</td></tr><tr><td colspan="3" align="left" rowspan="1">Age groups (n = 8744)</td></tr><tr><td align="left" rowspan="1" colspan="1">40&#x02013;49 years</td><td align="left" rowspan="1" colspan="1">405 (4.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">50&#x02013;59 years</td><td align="left" rowspan="1" colspan="1">1324 (15.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">60&#x02013;69 years</td><td align="left" rowspan="1" colspan="1">2932 (33.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">70&#x02013;79 years</td><td align="left" rowspan="1" colspan="1">3120 (35.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;80 years</td><td align="left" rowspan="1" colspan="1">963 (11.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="3" align="left" rowspan="1">Sex (n = 8808)</td></tr><tr><td align="left" rowspan="1" colspan="1">Men</td><td align="left" rowspan="1" colspan="1">7022 (79.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Women</td><td align="left" rowspan="1" colspan="1">1786 (20.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Height cm mean (SD) (n = 9124)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">166.1 &#x000b1; 7.7 (161&#x02013;171)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight kg. mean (SD) (n = 9017)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">76.3 &#x000b1; 12.1 (69&#x02013;84)</td></tr><tr><td colspan="3" align="left" rowspan="1">Body mass index (BMI) (n = 8930)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;25 kg/m<sup>2</sup></td><td align="left" rowspan="1" colspan="1">2090 (23.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">25&#x02013;29 kg/m<sup>2</sup></td><td align="left" rowspan="1" colspan="1">4677 (52.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">30&#x02013;34 kg/m<sup>2</sup></td><td align="left" rowspan="1" colspan="1">1735 (19.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">35&#x02013;39 kg/m<sup>2</sup></td><td align="left" rowspan="1" colspan="1">341 (3.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;40 kg/m<sup>2</sup></td><td align="left" rowspan="1" colspan="1">87 (1.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="3" align="left" rowspan="1">Smoking (n = 9347)</td></tr><tr><td align="left" rowspan="1" colspan="1">Never</td><td align="left" rowspan="1" colspan="1">1500 (16.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ex-smoker</td><td align="left" rowspan="1" colspan="1">5737 (61.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Current smoker</td><td align="left" rowspan="1" colspan="1">2110 (22.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Years since COPD diagnosis (n = 7157)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9.7 &#x000b1; 7.9</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV<sub>1</sub>% predicted (n = 7214)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">55.1 &#x000b1; 14.3 (45&#x02013;66)</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV<sub>1</sub>/FVC % (n = 5850)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">61.6 &#x000b1; 14.4 (52&#x02013;70)</td></tr><tr><td colspan="3" align="left" rowspan="1">Severity of COPD (n = 9049)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">3062 (33.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">4464 (49.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">1523 (16.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="3" align="left" rowspan="1">MRC dyspnea scale (n = 9211)</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1353 (14.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">4237 (46.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2293 (24.9)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1018 (11.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">310 (3.4)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-copd-3-683"><p>Abbreviations: COPD, chronic obstructive pulmonary disease; FEV<sub>1</sub>, forced expiratory volume in one second; FVC, forced vital capacity; MRC, Medical Research Council; SD, standard deviation.</p></fn><fn id="tfn2-copd-3-683"><label>*</label><p><bold>Note:</bold> 25th&#x02013;75th percentile.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-copd-3-683" position="float"><label>Table 2</label><caption><p>Quality of life in patients with COPD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">SF-12 questionnaire</th><th align="left" rowspan="1" colspan="1">Mean &#x000b1; SD</th><th align="left" rowspan="1" colspan="1">No patients (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Physical component summary (PCS-12)</td><td align="left" rowspan="1" colspan="1">36.8 &#x000b1; 10.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mental component summary (MCS-12)</td><td align="left" rowspan="1" colspan="1">47.2 &#x000b1; 11.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="3" align="left" rowspan="1">SF-12 scales</td></tr><tr><td align="left" rowspan="1" colspan="1">Physical functioning</td><td align="left" rowspan="1" colspan="1">38.6 &#x000b1; 32.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Role physical</td><td align="left" rowspan="1" colspan="1">44.8 &#x000b1; 46.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Bodily pain</td><td align="left" rowspan="1" colspan="1">64.3 &#x000b1; 29.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">General health</td><td align="left" rowspan="1" colspan="1">30.9 &#x000b1; 19.5</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Vitality</td><td align="left" rowspan="1" colspan="1">43.4 &#x000b1; 26.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Social functioning</td><td align="left" rowspan="1" colspan="1">65.9 &#x000b1; 27.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Emotional role</td><td align="left" rowspan="1" colspan="1">73.1 &#x000b1; 41.5</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mental health</td><td align="left" rowspan="1" colspan="1">63.1 &#x000b1; 20.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="3" align="left" rowspan="1">Physical domain (n = 9,405)</td></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;60 points)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">26 (0.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal (40&#x02013;60 points)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3714 (39.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Low (&#x0003c;40 points)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5665 (60.2)</td></tr><tr><td colspan="3" align="left" rowspan="1">Mental domain (n = 9,405)</td></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;60 points)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">613 (6.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal (40&#x02013;60 points)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6373 (67.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Low (&#x0003c;40 points)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2419 (25.7)</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-copd-3-683"><p><bold>Abbreviations:</bold> COPD, chronic obstructive pulmonary disease; SD, standard deviation; SF-12, Medical Outcomes Study Short Form 12 Health Survey Questionnaire.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-copd-3-683" position="float"><label>Table 3</label><caption><p>Differences in HRQL according to age and severity of COPD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th colspan="3" align="left" rowspan="1">Physical domain</th><th colspan="3" align="left" rowspan="1">Mental domain</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th colspan="6" align="left" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">High &#x0003e;60 points</th><th align="left" rowspan="1" colspan="1">Normal 40&#x02013;60 points</th><th align="left" rowspan="1" colspan="1">Low &#x0003c;40 points</th><th align="left" rowspan="1" colspan="1">High &#x0003e;60 points</th><th align="left" rowspan="1" colspan="1">Normal 40&#x02013;60 points</th><th align="left" rowspan="1" colspan="1">Low &#x0003c;40 points</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1">Age groups, years</td></tr><tr><td align="left" rowspan="1" colspan="1">40&#x02013;49 (n = 2193)</td><td align="left" rowspan="1" colspan="1">10 (0.5)</td><td align="left" rowspan="1" colspan="1">1112 (50.7)</td><td align="left" rowspan="1" colspan="1">1071 (48.8)</td><td align="left" rowspan="1" colspan="1">145 (6.6)</td><td align="left" rowspan="1" colspan="1">1546 (70.5)</td><td align="left" rowspan="1" colspan="1">502 (22.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">50&#x02013;59 (n = 1990)</td><td align="left" rowspan="1" colspan="1">3 (0.2)</td><td align="left" rowspan="1" colspan="1">742 (37.3)</td><td align="left" rowspan="1" colspan="1">1245 (62.6)</td><td align="left" rowspan="1" colspan="1">131 (6.6)</td><td align="left" rowspan="1" colspan="1">1384 (69.5)</td><td align="left" rowspan="1" colspan="1">475 (23.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">60&#x02013;69 (n = 1382)</td><td align="left" rowspan="1" colspan="1">2 (0.1)</td><td align="left" rowspan="1" colspan="1">439 (31.8)</td><td align="left" rowspan="1" colspan="1">941 (68.1)</td><td align="left" rowspan="1" colspan="1">80 (5.8)</td><td align="left" rowspan="1" colspan="1">914 (66.1)</td><td align="left" rowspan="1" colspan="1">388 (28.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">70&#x02013;79 (n = 519)</td><td align="left" rowspan="1" colspan="1">2 (0.4)</td><td align="left" rowspan="1" colspan="1">139 (26.8)</td><td align="left" rowspan="1" colspan="1">378 (72.8)</td><td align="left" rowspan="1" colspan="1">25 (4.8)</td><td align="left" rowspan="1" colspan="1">330 (63.6)</td><td align="left" rowspan="1" colspan="1">164 (31.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;80 (n = 1073)</td><td align="left" rowspan="1" colspan="1">2 (0.2)</td><td align="left" rowspan="1" colspan="1">344 (32.1)</td><td align="left" rowspan="1" colspan="1">727 (67.8)</td><td align="left" rowspan="1" colspan="1">79 (7.4)</td><td align="left" rowspan="1" colspan="1">678 (63.2)</td><td align="left" rowspan="1" colspan="1">316 (25.9)</td></tr><tr><td colspan="7" align="left" rowspan="1">COPD severity</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild (n = 3062)</td><td align="left" rowspan="1" colspan="1">16 (0.5)</td><td align="left" rowspan="1" colspan="1">1876 (61.3)</td><td align="left" rowspan="1" colspan="1">1170 (38.2)</td><td align="left" rowspan="1" colspan="1">179 (5.8)</td><td align="left" rowspan="1" colspan="1">2323 (75.9)</td><td align="left" rowspan="1" colspan="1">560 (18.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate (n = 4464)</td><td align="left" rowspan="1" colspan="1">9 (0.2)</td><td align="left" rowspan="1" colspan="1">1425 (31.9)</td><td align="left" rowspan="1" colspan="1">3030 (67.9)</td><td align="left" rowspan="1" colspan="1">284 (6.4)</td><td align="left" rowspan="1" colspan="1">3000 (67.2)</td><td align="left" rowspan="1" colspan="1">1180 (26.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe (n = 1523)</td><td align="left" rowspan="1" colspan="1">1 (0.1)</td><td align="left" rowspan="1" colspan="1">282 (18.5)</td><td align="left" rowspan="1" colspan="1">1240 (81.4)</td><td align="left" rowspan="1" colspan="1">130 (8.5)</td><td align="left" rowspan="1" colspan="1">815 (53.5)</td><td align="left" rowspan="1" colspan="1">578 (38.0)</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-copd-3-683"><p><bold>Abbreviations:</bold> COPD, chronic obstructive pulmonary disease; HRQOL, health-related quality of life.</p></fn><fn id="tfn5-copd-3-683"><p><bold>Note:</bold> Percentages in parenthesis.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-copd-3-683" position="float"><label>Table 4</label><caption><p>Management of patients with COPD: nonpharmacological and pharmacological treatment in the previous 12 months</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Management</th><th align="left" rowspan="1" colspan="1">Total population (n = 9405)</th><th colspan="3" align="left" rowspan="1">Health-related quality of life</th><th colspan="4" align="left" rowspan="1">Severity of COPD</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="7" align="left" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Normal (n = 5747)</th><th align="left" rowspan="1" colspan="1">Low (n = 3658)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="left" rowspan="1" colspan="1">Mild (n = 3062)</th><th align="left" rowspan="1" colspan="1">Moderate (n = 4464)</th><th align="left" rowspan="1" colspan="1">Severe (n = 1523)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Nonpharmacological therapy</td><td align="left" rowspan="1" colspan="1">4479 (47.6)</td><td align="left" rowspan="1" colspan="1">2568 (44.7)</td><td align="left" rowspan="1" colspan="1">1911 (52.2)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">1313 (42.9)</td><td align="left" rowspan="1" colspan="1">2134 (47.8)</td><td align="left" rowspan="1" colspan="1">892 (58.6)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking cessation counseling</td><td align="left" rowspan="1" colspan="1">2263 (24.1)</td><td align="left" rowspan="1" colspan="1">1450 (25.2)</td><td align="left" rowspan="1" colspan="1">813 (22.2)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">811 (26.5)</td><td align="left" rowspan="1" colspan="1">1032 (23.1)</td><td align="left" rowspan="1" colspan="1">355 (23.3)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Stop smoking treatment</td><td align="left" rowspan="1" colspan="1">385 (4.1)</td><td align="left" rowspan="1" colspan="1">239 (4.2)</td><td align="left" rowspan="1" colspan="1">146 (4.0)</td><td align="left" rowspan="1" colspan="1">0.689</td><td align="left" rowspan="1" colspan="1">136 (4.4)</td><td align="left" rowspan="1" colspan="1">184 (4.1)</td><td align="left" rowspan="1" colspan="1">55 (3.6)</td><td align="left" rowspan="1" colspan="1">0.411</td></tr><tr><td align="left" rowspan="1" colspan="1">Oxygen therapy</td><td align="left" rowspan="1" colspan="1">813 (8.6)</td><td align="left" rowspan="1" colspan="1">235 (4.1)</td><td align="left" rowspan="1" colspan="1">578 (15.8)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">47 (1.5)</td><td align="left" rowspan="1" colspan="1">305 (6.8)</td><td align="left" rowspan="1" colspan="1">434 (28.5)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Rehabilitation</td><td align="left" rowspan="1" colspan="1">947 (10.1)</td><td align="left" rowspan="1" colspan="1">457 (8.0)</td><td align="left" rowspan="1" colspan="1">490 (13.4)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">194 (6.3)</td><td align="left" rowspan="1" colspan="1">500 (11.2)</td><td align="left" rowspan="1" colspan="1">233 (15.3)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Pharmacological treatment</td><td align="left" rowspan="1" colspan="1">7980 (84.8)</td><td align="left" rowspan="1" colspan="1">4727 (82.3)</td><td align="left" rowspan="1" colspan="1">3253 (88.9)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">2416 (78.9)</td><td align="left" rowspan="1" colspan="1">3872 (86.7)</td><td align="left" rowspan="1" colspan="1">1391 (91.3)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Bronchodilators</td><td align="left" rowspan="1" colspan="1">6935 (73.7)</td><td align="left" rowspan="1" colspan="1">4176 (72.7)</td><td align="left" rowspan="1" colspan="1">2759 (75.4)</td><td align="left" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">2123 (69.3)</td><td align="left" rowspan="1" colspan="1">3319 (74.4)</td><td align="left" rowspan="1" colspan="1">1232 (80.9)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Short-acting &#x003b2;<sub>2</sub>-agonists</td><td align="left" rowspan="1" colspan="1">2539 (27.0)</td><td align="left" rowspan="1" colspan="1">1449 (25.2)</td><td align="left" rowspan="1" colspan="1">1090 (29.8)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">747 (24.4)</td><td align="left" rowspan="1" colspan="1">1181 (26.5)</td><td align="left" rowspan="1" colspan="1">510 (33.5)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Long-acting &#x003b2;<sub>2</sub>-agonists</td><td align="left" rowspan="1" colspan="1">2167 (23.0)</td><td align="left" rowspan="1" colspan="1">1283 (22.3)</td><td align="left" rowspan="1" colspan="1">884 (24.2)</td><td align="left" rowspan="1" colspan="1">0.038</td><td align="left" rowspan="1" colspan="1">589 (19.2)</td><td align="left" rowspan="1" colspan="1">1059 (23.7)</td><td align="left" rowspan="1" colspan="1">424 (27.8)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Short-acting anticholinergics</td><td align="left" rowspan="1" colspan="1">1552 (16.5)</td><td align="left" rowspan="1" colspan="1">900 (15.7)</td><td align="left" rowspan="1" colspan="1">652 (17.8)</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">414 (13.5)</td><td align="left" rowspan="1" colspan="1">765 (17.1)</td><td align="left" rowspan="1" colspan="1">316 (20.7)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Long-acting anticholinergics</td><td align="left" rowspan="1" colspan="1">3953 (42.0)</td><td align="left" rowspan="1" colspan="1">2408 (41.9)</td><td align="left" rowspan="1" colspan="1">1545 (42.2)</td><td align="left" rowspan="1" colspan="1">0.747</td><td align="left" rowspan="1" colspan="1">1154 (37.7)</td><td align="left" rowspan="1" colspan="1">1951 (43.7)</td><td align="left" rowspan="1" colspan="1">710 (46.6)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Fixed combinations</td><td align="left" rowspan="1" colspan="1">5410 (57.5)</td><td align="left" rowspan="1" colspan="1">3176 (55.3)</td><td align="left" rowspan="1" colspan="1">2234 (61.1)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">1585 (51.8)</td><td align="left" rowspan="1" colspan="1">2657 (59.5)</td><td align="left" rowspan="1" colspan="1">986 (64.7)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Anticholinergics and short-acting &#x003b2;<sub>2</sub>-agonists</td><td align="left" rowspan="1" colspan="1">687 (7.3)</td><td align="left" rowspan="1" colspan="1">395 (6.9)</td><td align="left" rowspan="1" colspan="1">292 (8.0)</td><td align="left" rowspan="1" colspan="1">0.043</td><td align="left" rowspan="1" colspan="1">197 (6.4)</td><td align="left" rowspan="1" colspan="1">332 (7.4)</td><td align="left" rowspan="1" colspan="1">134 (8.8)</td><td align="left" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">Inhaled steroids and long-acting &#x003b2;<sub>2</sub>-agonists</td><td align="left" rowspan="1" colspan="1">5155 (54.8)</td><td align="left" rowspan="1" colspan="1">3022 (52.6)</td><td align="left" rowspan="1" colspan="1">2133 (58.3)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">1510 (49.3)</td><td align="left" rowspan="1" colspan="1">2525 (56.6)</td><td align="left" rowspan="1" colspan="1">950 (62.4)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Steroids</td><td align="left" rowspan="1" colspan="1">1865 (19.8)</td><td align="left" rowspan="1" colspan="1">899 (15.6)</td><td align="left" rowspan="1" colspan="1">966 (26.4)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">359 (11.7)</td><td align="left" rowspan="1" colspan="1">949 (21.3)</td><td align="left" rowspan="1" colspan="1">479 (31.5)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Oral</td><td align="left" rowspan="1" colspan="1">701 (7.5)</td><td align="left" rowspan="1" colspan="1">226 (3.9)</td><td align="left" rowspan="1" colspan="1">465 (13.0)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">99 (3.2)</td><td align="left" rowspan="1" colspan="1">318 (7.1)</td><td align="left" rowspan="1" colspan="1">251 (16.5)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Inhaled</td><td align="left" rowspan="1" colspan="1">1492 (15.9)</td><td align="left" rowspan="1" colspan="1">773 (13.5)</td><td align="left" rowspan="1" colspan="1">719 (19.7)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">304 (9.9)</td><td align="left" rowspan="1" colspan="1">775 (176.4)</td><td align="left" rowspan="1" colspan="1">351 (23.0)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Antibiotics</td><td align="left" rowspan="1" colspan="1">4671 (49.7)</td><td align="left" rowspan="1" colspan="1">2752 (47.9)</td><td align="left" rowspan="1" colspan="1">1919 (52.5)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">1462 (47.7)</td><td align="left" rowspan="1" colspan="1">2210 (49.5)</td><td align="left" rowspan="1" colspan="1">807 (53.0)</td><td align="left" rowspan="1" colspan="1">0.003</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-copd-3-683"><p><bold>Abbreviations:</bold> COPD, chronic obstructive pulmonary disease.</p></fn><fn id="tfn7-copd-3-683"><p><bold>Note:</bold> Percentages in parenthesis.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>